3-Methyl-3-methylethylamino-butan | 84310-25-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Methyl-3-methylethylamino-butan
• 英文别名: N-ethyl-N,2-dimethylbutan-2-amine
• CAS: 84310-25-8
• 化学式: C₈H₁₉N
• 分子量: 129.246
• InChiKey: CGUJPOFYCZJARL-UHFFFAOYSA-N

物化性质

• 沸点：
  135 °C
• 密度：
  0.769±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 tert-pentylethylamine 在 甲酸 作用下， 生成 3-Methyl-3-methylethylamino-butan
  参考文献：
  名称：

  Khorlin,A.Ya. et al., Journal of general chemistry of the USSR, 1961, vol. 31, p. 1708 - 1710

  摘要：

  DOI：

文献信息

• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Honigberg Lee

  公开号：US20120178753A1

  公开（公告）日：2012-07-12

  Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.

  本文介绍了不可逆激酶抑制剂化合物、合成此类不可逆抑制剂的方法，以及使用此类不可逆抑制剂治疗疾病的方法。此外，本文还介绍了确定蛋白质（包括激酶）适当的不可逆抑制剂的方法、测定和系统。
• Tetracycline Compounds
  申请人：Chen Chi-Li

  公开号：US20120135968A1

  公开（公告）日：2012-05-31

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物或其药学上可接受的盐。结构式I的变量在此定义。同时还描述了包含结构式I化合物的药物组合物及其治疗用途。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• Aqueous ink composition for use in an ink-jet printer
  申请人：SEIKO EPSON CORPORATION

  公开号：EP0838508A2

  公开（公告）日：1998-04-29

  An aqueous ink composition for ink jet printers, which gives reliable printing performance and yields printed images which have excellent print quality and which dry rapidly is disclosed. The ink compositions are suitable for printing on plain paper. The ink comprises water as the principal solvent, an anionic colorant, pectic acid, a base, and at least one of a penetrable solvent and/or a penetrability-imparting surfactant. The pectic acid is composed primarily of α-1,4 linked polygalacturonic acid having a degree of esterification not more than 5% where the degree of esterification is defined as the percentage of the total number of galacturonic acid units in the pectic acid which are esterified.

  本发明公开了一种用于喷墨打印机的水性油墨组合物，该组合物具有可靠的打印性能，可打印出打印质量极佳且干燥迅速的图像。这种油墨组合物适用于在普通纸上打印。油墨包括作为主溶剂的水、阴离子着色剂、果胶酸、碱和至少一种可渗透溶剂和/或渗透性促进表面活性剂。果胶酸主要由α-1,4 连接的聚半乳糖醛酸组成，其酯化程度不超过 5%，其中酯化程度定义为果胶酸中酯化的半乳糖醛酸单位总数的百分比。
• TETRACYCLINE COMPOUNDS
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：EP2427425B1

  公开（公告）日：2017-03-08